Eli Lilly is making strategic moves to expand its obesity medication Zepbound beyond weight management, demonstrating promising results when combined with its autoimmune therapeutic Taltz for treating patients with both psoriasis and obesity. As reported by TechTarget.com, Phase 3 trial data from the Together-PsO study reveals that this dual-drug approach significantly outperforms monotherapy in addressing the complex interplay between chronic inflammatory skin disease and metabolic disorder.
The clinical evidence is compelling. Among 274 psoriasis patients studied over 36 weeks, those receiving the Zepbound–Taltz combination achieved complete skin clearance while simultaneously losing at least 10% of body weight at a rate of 27%, compared to just 6% of patients on Taltz monotherapy. More striking still, combination therapy patients demonstrated a 40% greater likelihood of achieving complete skin clearance (PASI 100 response) than those receiving Taltz alone. These results represent a meaningful advancement for a particularly challenging patient population.
The study population underscores the clinical significance of these findings. Participants averaged a BMI exceeding 39 across both treatment groups, representing individuals with particularly difficult-to-treat psoriasis and substantial disease burden. This is particularly noteworthy because research consistently demonstrates that individuals with higher BMI are less likely to achieve complete skin clearance with conventional therapies alone. By targeting both the inflammatory dermatological component through Taltz (an IL-17A antagonist) and the metabolic component through Zepbound (a GLP-1 dual agonist), the combination approach addresses the full scope of disease burden these patients face.
The rationale for combination therapy is grounded in epidemiology. Approximately 60% of Americans with psoriasis struggle with concurrent obesity or excess weight, often accompanied by weight-related comorbidities. This substantial overlap highlights a critical gap in treatment approaches that historically address these conditions in isolation. Adrienne Brown, Lilly’s immunology chief, eloquently captured this paradigm shift, noting that for patients at the intersection of these chronic inflammatory diseases, the PASI 100 results “demonstrate what becomes possible when we address both simultaneously.”
These findings build upon previous encouraging data from late-stage trials in psoriatic arthritis, where 32% of Zepbound–Taltz recipients achieved 50% disease activity improvement while losing at least 10% body weight, compared to 1% of Taltz-only patients meeting both endpoints. Together, these results suggest a transformative potential for comprehensive treatment strategies targeting concurrent inflammatory and metabolic conditions.
Dr. Mark Lebwohl, principal investigator and Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai, characterized the PASI 100 results as “especially remarkable” given the challenging patient population studied, emphasizing that the findings reinforce psoriasis as an obesity-related condition deserving integrated therapeutic approaches.
While regulatory approval for expanded indications remains pending, Lilly has committed to submitting full study details to peer-reviewed journals and regulators, though no specific timeline was announced. The Together-PsO trial represents a promising proof-of-concept for treating complex multisystem diseases through coordinated pharmacological intervention, potentially reshaping clinical practice and improving outcomes for millions of patients living with both psoriasis and obesity.
